NewsBenzingaReported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review Reported Earlier, DBV Technologies Submits BLA To FDA For VIASKIN Peanut Patch In Children Aged 4-7 With Peanut Allergy, Requests Priority Review Benzinga 2026.09.30 07:43 (GMT+0) Open on Benzinga Other news TSMC Weighs Texas Chip Investment Beyond Its $265B Arizona Plan - TipRanks.com Gene Munster Says SPCX Stock Could More Than Double as Starship Supercharges Launch Cadence: ‘Bigger Week Than Most Investors Realize’ Sagimet Biosciences Prices $115M Offer Of 8,750,010 Shares And Warrants At $10.00/Unit Citigroup Downgrades Moderna to Sell, Raises Price Target to $80 Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12 B of A Securities Upgrades Grocery Outlet Holding to Buy, Raises Price Target to $15
Gene Munster Says SPCX Stock Could More Than Double as Starship Supercharges Launch Cadence: ‘Bigger Week Than Most Investors Realize’
